FDA Approvals: NitroMist, Nexium, Taxotere.

November 9, 2007 — The US Food and Drug Justice (FDA) has approved a nitroglycerin lingual 400-µg/actuation dispenser for the acute rilievo of an offence or acute prophylaxis of inflammatory disease pectoris; an oral break compound of delayed-release esomeprazole magnesium for use in patients who have effort swallowing pills due to gastroesophageal flow disease and other conditions; and a new data point for docetaxel intravenous extract, allowing its use in aggregation with cisplatin and fluorouracil for the stimulation management of inoperable, locally advanced head and neck metastatic tumor.Nitroglycerin Lingual Cloud (NitroMist) for Prevention and Communication of Inflammatory disease.
On November 2, the FDA approved nitroglycerin lingual 400-µg/actuation cloud (NitroMist, made by NovaDel Pharma, Inc, and marketed by Par Pharmaceutical Companies, Inc) for the acute restitution of an formulation or acute prophylaxis of cardiopathy pectoris due to coronary arterial blood vessel disease. Each container contains 230 metered sprays.